Discover
ABCL
AbCellera Biologics Inc.
7.60
2 x 5.61
2 x 9.36
bid
ask
-
0.25
3.18%
2 @ 07:39 AM
7.50 -0.10 (1.32%)
| Ytd | 122.22% | |
| 1y | 117.77% |
7.26
day range
7.85
2.75
52 week range
8.42
| Open | 7.69 | Prev Close | 7.85 | Low | 7.26 | High | 7.85 | Mkt Cap | 2.32B |
| Vol | 7.97M | Avg Vol | 7.57M | EPS | -0.48 | P/E | N/A | Forward P/E | -10.56 |
| Beta | 1.20 | Short Ratio | 6.05 | Inst. Own | 42.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.27 | 200-d Avg | 4.36 | 1yr Est | 10.43 |
| Income Statement | |||
| Total Revenue | 8.32M | ||
| Revenues (USD) | 8.32M | ||
| Gross Profit | 8.32M | ||
| Operating Expenses | 65.83M | ||
| Research and Development Expense | 46.66M | ||
| Selling, General and Administrative Expense | 12.33M | ||
| Operating Income | -57.52M | ||
| Interest Expense | -3.64M | ||
| Income Tax Expense | -6.37M | ||
| Net Income | -43.16M | ||
| Net Income Common Stock | -43.16M | ||
| Net Income Common Stock (USD) | -43.16M | ||
| Consolidated Income | -43.16M | ||
| Earnings per Basic Share | -0.14 | ||
| Earnings per Basic Share (USD) | -0.14 | ||
| Earnings per Diluted Share | -0.14 | ||
| Earning Before Interest & Taxes (EBIT) | -53.18M | ||
| Earning Before Interest & Taxes (USD) | -53.18M | ||
| Weighted Average Shares | 303.07M | ||
| Weighted Average Shares Diluted | 303.07M | ||
| Balance Sheet | |||
| Cash and Equivalents | 102.06M | ||
| Cash and Equivalents (USD) | 102.06M | ||
| Investments | 492.98M | ||
| Investments Current | 427.67M | ||
| Investments Non-Current | 65.31M | ||
| Trade and Non-Trade Receivables | 36.76M | ||
| Current Assets | 664.60M | ||
| Property, Plant & Equipment Net | 422.81M | ||
| Total Assets | 1.31B | ||
| Total Debt | 134.31M | ||
| Current Liabilities | 47.29M | ||
| Debt Non-Current | 134.31M | ||
| Total Liabilities | 369.03M | ||
| Accumulated Retained Earnings (Deficit) | -72.65M | ||
| Accumulated Other Comprehensive Income | -2.42M | ||
| Shareholders Equity | 938.08M | ||
| Shareholders Equity (USD) | 938.08M | ||
| Assets Non-Current | 642.52M | ||
| Total Debt (USD) | 134.31M | ||
| Deferred Revenue | 7.74M | ||
| Goodwill and Intangible Assets | 85.27M | ||
| Liabilities Non-Current | 321.74M | ||
| Trade and Non-Trade Payables | 39.55M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 8.65M | ||
| Net Cash Flow from Financing | 7.19M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -51.45M | ||
| Capital Expenditure | -3.83M | ||
| Issuance (Repayment) of Debt Securities | 7.19M | ||
| Net Cash Flow from Investing | -25.08M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -22.61M | ||
| Net Cash Flow from Operations | -33.52M | ||
| Effect of Exchange Rate Changes on Cash | -38.00K | ||
| Share Based Compensation | 12.01M | ||